Skip to main content
MRNA
NASDAQ Life Sciences

葛兰素史克的RSV疫苗获得FDA批准，扩大适用范围至年轻成年人，加剧与Moderna的竞争

feedReported by Reuters
Sentiment info
Negative
Importance info
8
Price
$53.49
Mkt Cap
$21.086B
52W Low
$22.28
52W High
$59.55
Market data snapshot near publication time

summarizeSummary

葛兰素史克获得FDA批准，扩大其RSV疫苗Arexvy的适用范围，包括18至49岁的成年人，他们患下呼吸道疾病的风险增加。这显著扩大了葛兰素史克疫苗的潜在市场，之前该疫苗仅获得批准用于老年人。这种发展加剧了与Moderna的mRESVIA和辉瑞的Abrysvo在RSV疫苗市场的竞争，特别是在这一新批准的年轻成年人群体中，葛兰素史克估计有2100万有风险的个体。关键竞争对手的扩大批准可能会对Moderna的未来市场份额和其自身RSV疫苗的收入预测施加压力

在该公告发布时，MRNA的交易价格为$53.49，交易所为NASDAQ，所属行业为Life Sciences，市值约为$210.9亿。 52周交易区间为$22.28至$59.55。 这则新闻被评估为消极市场情绪，重要性评分为8/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed MRNA - Latest Insights

MRNA
Apr 21, 2026, 9:40 AM EDT
Source: Access Newswire
Importance Score:
8
Moderna's mCOMBRIAX, World's First Flu-COVID Combo Vaccine, Gets EU Marketing Authorization
Sentiment: Positive
View Wiseek Article
MRNA
Mar 13, 2026, 6:58 AM EDT
Source: Reuters
Importance Score:
8
GSK's RSV Vaccine Gains Key FDA Approval for Younger Adults, Intensifying Competition for Moderna
Sentiment: Negative
View Wiseek Article
MRNA
Mar 04, 2026, 8:20 PM EST
Filing Type: 8-K
Importance Score:
8
Moderna Settles Patent Litigation for Up to $2.25B, Securing Royalty-Free Rights for Key Vaccines
Sentiment: Neutral
View Wiseek Article
MRNA
Mar 04, 2026, 10:10 AM EST
Source: Dow Jones Newswires
Importance Score:
9
Moderna Settles Major Covid-19 Vaccine Patent Suit for $2.25 Billion, Shares Rise
Sentiment: Positive
View Wiseek Article
MRNA
Mar 03, 2026, 4:28 PM EST
Source: Dow Jones Newswires
Importance Score:
8
Moderna to Appeal to Federal Circuit Court, Citing Government-Contractor Immunity Defense
Sentiment: Neutral
View Wiseek Article
MRNA
Mar 03, 2026, 4:25 PM EST
Source: Reuters
Importance Score:
8
Moderna Projects $4.5B-$5B Year-End Cash, Reveals $950M Q1 Settlement Charge
Sentiment: Neutral
View Wiseek Article
MRNA
Mar 03, 2026, 3:04 PM EST
Source: Wiseek News
Importance Score:
8
Moderna's Cancer Vaccine Shows Reduced Recurrence, FDA Reverses Flu Vaccine Review
Sentiment: Positive
View Wiseek Article
MRNA
Feb 27, 2026, 7:00 AM EST
Source: Acceswire
Importance Score:
8
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
Sentiment: Positive
View Wiseek Article
MRNA
Feb 20, 2026, 4:02 PM EST
Filing Type: 10-K
Importance Score:
8
Moderna Reports $2.8B Net Loss in 2025 Amidst 40% Revenue Decline, Discontinues CMV Vaccine in Congenital CMV
Sentiment: Negative
View Wiseek Article
MRNA
Feb 13, 2026, 7:02 AM EST
Filing Type: 8-K
Importance Score:
7
Moderna Reports Q4 & FY25 Results, Projects 10% Revenue Growth in 2026, Faces US Flu Vaccine Setback
Sentiment: Neutral
View Wiseek Article